List of Tricor drug patents
Tricor is owned by Abbvie.
Tricor contains Fenofibrate.
Tricor has a total of 2 drug patents out of which 0 drug patents have expired.
Tricor was authorised for market use on 05 November, 2004.
Tricor is available in tablet;oral dosage forms.
Tricor can be used as adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v).
The generics of Tricor are possible to be released after 21 February, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(18 days from now) | |
| US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(18 days from now) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v)
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic